title: [Efficacy of quadropril (spirapril) vs capropril in treatment of essential hypertension].
abstract: OBJECTIVE
  To compare the efficacy of monotherapy with quadropril (spirapril) vs captopril in essential hypertension.
  
  
  METHODS
  20 female patients aged 55 +/- 2 years with moderate hypertension (WHO classification) were included in the study. 16 patients had congestive heart failure stage II NYHA and 4 patients stage III NYHA. ECG and echocardiography were performed in all the patients. Two patient groups of 10 patients were treated for 6 weeks. Group 1 received 6 mg quadropril once daily. Group 2 received 25 mg captopril 3 times daily. The therapy was considered to be efficient if diastolic pressure (BP) was reduced to 90 +/- 5 mm Hg and systolic BP to 140 +/- 10 mm Hg from baseline values in the range of 210/120-170/100 mm Hg.
  
  
  RESULTS
  The hypotensive effect of quadropril resulted in stabilisation of BP during the second week of therapy. A significant BP decrease was achieved at the end of 6 week therapy. Systolic BP fell from 178.8 +/- 3.2 to 145 +/- 5.6 mm Hd and diastolic BP from 109.7 +/- 1.2 to 92.4 +/- 1.7 mm Hg. Central and cardiac hemodynamic parameters improved. In one patient the condition improved from CHF stage III to stage II NYHA. No adverse effects were observed. A hypotensive effect of captopril reduced significantly systolic blood pressure from 182.1 +/- 2.7 to 150 +/- 4.6 mm Hg and diastolic BP from 110.4 +/- 1.1 to 100.1 +/- 1.9 mm Hg. Two patients developed adverse effects: cough and chest dyscomfort.
  
  
  CONCLUSIONS
  Quadropril monotherapy showed to be more effective in diastolic BP decrease compared with captopril monotherapy and had advantages in one daily dose regimen, absence of the first dose effect and side effects.
authors.forename: D S
authors.initials: DS
authors.lastname: Polimbetov
authors.forename: V A
authors.initials: VA
authors.lastname: Kraĭsman
authors.forename: B G
authors.initials: BG
authors.lastname: Isaeva
authors.forename: F R
authors.initials: FR
authors.lastname: Aliev
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000627:therapeutic use*; D004656:Enalapril / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005260:Female; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D011379:Prognosis; D012720:Severity of Illness Index; D014463:Ultrasonography; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; C052555:spirapril; D002216:Captopril
vernacular_title: Effektivnost' kvadroprila (spiraprila) i kaptoprila pri éssentsial'noĭ gipertonii (gipertonicheskoĭ bolezni).